trial · primary record
bi-4SCAR CD19/22 T cells
B Cell Malignancies
| Phase | Phase 1, Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 60 |
| Primary completion | 2030-12-31 |
| Primary endpoint | Safety of fourth generation bi-4SCARCD19/22 T cells in patients with B cell malignancies |
| Registry ID | NCT05432882 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-02T15:46:32.266Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT05432882
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.